{
    "organizations": [],
    "uuid": "6905aa33d4b36d11b50332038472c9c029609dd9",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-acceleron-pharma-q4-loss-per-share/brief-acceleron-pharma-q4-loss-per-share-0-62-idUSASB0C7SQ",
    "ord_in_thread": 0,
    "title": "BRIEF-Acceleron Pharma Q4 Loss Per Share $‍0.62​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 27 (Reuters) - Acceleron Pharma Inc:\n* ACCELERON REPORTS FOURTH QUARTER AND FULL YEAR 2017 OPERATING AND FINANCIAL RESULTS\n* ‍TOP-LINE RESULTS FROM MEDALIST AND BELIEVE PHASE 3 TRIALS OF LUSPATERCEPT ARE EXPECTED IN MID-2018​\n* ‍ON TRACK TO INITIATE A PHASE 2 TRIAL IN PULMONARY ARTERIAL HYPERTENSION IN 1H 2018​\n* QTRLY LOSS PER SHARE $‍0.62​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-28T05:55:00.000+02:00",
    "crawled": "2018-02-28T12:51:43.008+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "acceleron",
        "pharma",
        "inc",
        "acceleron",
        "report",
        "fourth",
        "quarter",
        "full",
        "year",
        "operating",
        "financial",
        "result",
        "result",
        "medalist",
        "believe",
        "phase",
        "trial",
        "luspatercept",
        "expected",
        "track",
        "initiate",
        "phase",
        "trial",
        "pulmonary",
        "arterial",
        "hypertension",
        "1h",
        "qtrly",
        "loss",
        "per",
        "share",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}